{"id":12571,"date":"2026-11-05T15:03:21","date_gmt":"2026-11-05T14:03:21","guid":{"rendered":"https:\/\/mumak.me\/?p=12571"},"modified":"2026-11-05T16:58:17","modified_gmt":"2026-11-05T15:58:17","slug":"rheinmetall-q3-2026-earnings-update","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/company-update\/rheinmetall-q3-2026-earnings-update\/","title":{"rendered":"Revolution Medicines \u2013 Q3 2026 Earnings Update"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"12571\" class=\"elementor elementor-12571 elementor-12570\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e1ac738 e-flex e-con-boxed e-con e-parent\" data-id=\"e1ac738\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b8e9f5a elementor-widget elementor-widget-text-editor\" data-id=\"b8e9f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\"><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a>, a component of the <strong>UMBRELLA Strategy<\/strong>, achieved a decisive milestone in the third quarter of 2026. With the approval and market launch of the cancer drug <strong>RASONQUE (Daraxonrasib)<\/strong> in the USA, the biotechnology company is transitioning from clinical development to commercialization.<\/p><p>In the first approximately five weeks after approval, the company already generated <strong>product revenue<\/strong> of <strong>nearly USD 198 million<\/strong>. At the same time, research and sales expenses rose significantly as further clinical studies and planned international expansion were advanced.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e410360 elementor-widget elementor-widget-gn_tradingview_chart\" data-id=\"e410360\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"gn_tradingview_chart.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t        <div class=\"gn-tv-widget gn-tv-widget--chart\" style=\"--gn-tv-height: 450px; --gn-tv-min-height: 450px;\" data-gn-tv-type=\"symbol-overview\" data-gn-tv-config=\"{&quot;lineWidth&quot;:2,&quot;lineType&quot;:0,&quot;chartType&quot;:&quot;area&quot;,&quot;showVolume&quot;:true,&quot;fontColor&quot;:&quot;rgb(106, 109, 120)&quot;,&quot;gridLineColor&quot;:&quot;rgba(46, 46, 46, 0.06)&quot;,&quot;volumeUpColor&quot;:&quot;rgba(34, 171, 148, 0.5)&quot;,&quot;volumeDownColor&quot;:&quot;rgba(247, 82, 95, 0.5)&quot;,&quot;backgroundColor&quot;:&quot;#ffffff&quot;,&quot;widgetFontColor&quot;:&quot;rgba(69, 56, 42, 1)&quot;,&quot;upColor&quot;:&quot;#22ab94&quot;,&quot;downColor&quot;:&quot;#f7525f&quot;,&quot;borderUpColor&quot;:&quot;#22ab94&quot;,&quot;borderDownColor&quot;:&quot;#f7525f&quot;,&quot;wickUpColor&quot;:&quot;#22ab94&quot;,&quot;wickDownColor&quot;:&quot;#f7525f&quot;,&quot;colorTheme&quot;:&quot;light&quot;,&quot;isTransparent&quot;:false,&quot;locale&quot;:&quot;en&quot;,&quot;chartOnly&quot;:false,&quot;scalePosition&quot;:&quot;right&quot;,&quot;scaleMode&quot;:&quot;Normal&quot;,&quot;fontFamily&quot;:&quot;Inter, -apple-system, BlinkMacSystemFont, Trebuchet MS, Roboto, Ubuntu, sans-serif&quot;,&quot;valuesTracking&quot;:&quot;1&quot;,&quot;changeMode&quot;:&quot;price-and-percent&quot;,&quot;symbols&quot;:[[&quot;NASDAQ:RVMD|12M&quot;]],&quot;dateRanges&quot;:[&quot;1d|1&quot;,&quot;1m|30&quot;,&quot;3m|60&quot;,&quot;12m|1D&quot;,&quot;60m|1W&quot;,&quot;all|1M&quot;],&quot;fontSize&quot;:&quot;10&quot;,&quot;headerFontSize&quot;:&quot;medium&quot;,&quot;autosize&quot;:true,&quot;width&quot;:&quot;100%&quot;,&quot;height&quot;:&quot;100%&quot;,&quot;noTimeScale&quot;:false,&quot;hideDateRanges&quot;:false,&quot;showMA&quot;:false,&quot;maLength&quot;:9,&quot;maLineColor&quot;:&quot;#2962FF&quot;,&quot;maLineWidth&quot;:1,&quot;hideMarketStatus&quot;:false,&quot;hideSymbolLogo&quot;:false}\">\n            <div class=\"gn-tv-widget__inner\">\n                <div class=\"gn-tv-widget__embed gn-tv-widget__chart\">\n                    <div class=\"tradingview-widget-container__widget\"><\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9a58f06 e-flex e-con-boxed e-con e-parent\" data-id=\"9a58f06\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2b6855b elementor-widget elementor-widget-text-editor\" data-id=\"2b6855b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-pm-slice=\"1 1 []\">Financial Key Figures \u2013 Q3 2026<\/h2><p data-pm-slice=\"1 1 []\"><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> achieved <strong>net product revenue of USD 197.6 million<\/strong> in the third quarter of 2026. In the prior-year quarter, the company had not reported any product revenues.<\/p><p data-pm-slice=\"1 1 []\">The <strong>Research and development expenses<\/strong> <strong>increased by approximately 59%<\/strong> to <strong>USD 417.1 million<\/strong>. The <strong>Sales and administrative expenses<\/strong> <strong>rose from USD 52.8 million to USD 153.3 million<\/strong>, particularly due to the build-out of commercial infrastructure.<\/p><p data-pm-slice=\"1 1 []\">The <strong>Net loss<\/strong> widened <strong>from USD 305.2 million to USD 407.5 million<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f904adb elementor-widget elementor-widget-html\" data-id=\"f904adb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t\n<style>\n\/* MUMAK Finanzkennzahlen *\/\n.mumak-financial {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --line: #E5E7E8;\n  font-family: inherit;\n  color: var(--navy);\n  max-width: 100%;\n  margin: 28px 0;\n}\n\n.mumak-financial * {\n  box-sizing: border-box;\n}\n\n.mumak-financial .mf-header {\n  border-left: 4px solid var(--gold);\n  padding-left: 17px;\n  margin-bottom: 22px;\n}\n\n.mumak-financial .mf-eyebrow {\n  color: var(--gold);\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.5px;\n  text-transform: uppercase;\n  margin-bottom: 7px;\n}\n\n.mumak-financial .mf-title {\n  font-size: clamp(21px, 3vw, 28px);\n  line-height: 1.25;\n  font-weight: 700;\n  color: var(--navy);\n  margin: 0 0 7px;\n}\n\n.mumak-financial .mf-subtitle {\n  font-size: 13px;\n  color: #697780;\n  margin: 0;\n}\n\n.mumak-financial .mf-kpis {\n  display: grid;\n  grid-template-columns: repeat(4, minmax(0, 1fr));\n  gap: 12px;\n  margin-bottom: 25px;\n}\n\n.mumak-financial .mf-kpi {\n  background: var(--cream);\n  border: 1px solid #EAE4DB;\n  border-radius: 9px;\n  padding: 18px 13px;\n  min-width: 0;\n}\n\n.mumak-financial .mf-value {\n  display: block;\n  font-size: clamp(19px, 2.3vw, 27px);\n  font-weight: 700;\n  color: var(--navy);\n  line-height: 1.2;\n  margin-bottom: 9px;\n  font-variant-numeric: tabular-nums;\n}\n\n.mumak-financial .mf-label {\n  display: block;\n  font-size: 12px;\n  font-weight: 600;\n  line-height: 1.4;\n}\n\n.mumak-financial .mf-detail {\n  display: block;\n  margin-top: 7px;\n  font-size: 11px;\n  color: #7A858A;\n}\n\n.mumak-financial .mf-section-title {\n  font-size: 18px;\n  font-weight: 700;\n  color: var(--navy);\n  margin: 0 0 13px;\n}\n\n.mumak-financial .mf-table-wrap {\n  width: 100%;\n  overflow-x: auto;\n  border: 1px solid var(--line);\n  border-radius: 9px;\n  margin-bottom: 24px;\n}\n\n.mumak-financial table {\n  width: 100%;\n  min-width: 470px;\n  border-collapse: collapse;\n  border: 0;\n  margin: 0;\n  font-size: 13px;\n  background: #FFFFFF;\n}\n\n.mumak-financial table thead th {\n  background: var(--navy);\n  color: #FFFFFF;\n  font-size: 11px;\n  letter-spacing: .5px;\n  text-transform: uppercase;\n  padding: 14px 15px;\n  border: 0;\n}\n\n.mumak-financial table th:first-child,\n.mumak-financial table td:first-child {\n  text-align: left;\n  width: 52%;\n}\n\n.mumak-financial table th:not(:first-child),\n.mumak-financial table td:not(:first-child) {\n  text-align: right;\n}\n\n.mumak-financial table tbody td {\n  padding: 13px 15px;\n  border: 0;\n  border-bottom: 1px solid var(--line);\n  vertical-align: middle;\n  font-variant-numeric: tabular-nums;\n}\n\n.mumak-financial table tbody tr:nth-child(even) {\n  background: #FAFAF9;\n}\n\n.mumak-financial table tbody tr:last-child td {\n  border-bottom: 0;\n}\n\n.mumak-financial .mf-amount {\n  font-weight: 600;\n}\n\n.mumak-financial .mf-outlook {\n  background: var(--cream);\n  border: 1px solid #EAE4DB;\n  border-left: 4px solid var(--gold);\n  border-radius: 8px;\n  padding: 22px;\n  margin-top: 8px;\n}\n\n.mumak-financial .mf-outlook-title {\n  font-size: 18px;\n  font-weight: 700;\n  margin: 0 0 18px;\n}\n\n.mumak-financial .mf-forecast {\n  display: grid;\n  grid-template-columns: repeat(2, minmax(0, 1fr));\n  gap: 18px;\n}\n\n.mumak-financial .mf-forecast-label {\n  display: block;\n  font-size: 12px;\n  color: #66747D;\n  margin-bottom: 7px;\n}\n\n.mumak-financial .mf-forecast-value {\n  display: block;\n  font-size: clamp(17px, 2.4vw, 23px);\n  font-weight: 700;\n  line-height: 1.3;\n  overflow-wrap: anywhere;\n}\n\n.mumak-financial .mf-source {\n  margin-top: 15px;\n  font-size: 11px;\n  line-height: 1.6;\n  color: #758087;\n}\n\n\/* Mobile Darstellung *\/\n@media (max-width: 767px) {\n  .mumak-financial .mf-kpis {\n    grid-template-columns: repeat(2, minmax(0, 1fr));\n    gap: 9px;\n  }\n\n  .mumak-financial .mf-kpi {\n    padding: 15px 11px;\n  }\n\n  .mumak-financial .mf-forecast {\n    grid-template-columns: 1fr;\n    gap: 17px;\n  }\n\n  .mumak-financial .mf-outlook {\n    padding: 18px 15px;\n  }\n\n  .mumak-financial table {\n    font-size: 12px;\n  }\n  \n\n\/* BAYER \u2013 3 KPI CARDS PER ROW *\/\n.mumak-financial .mf-kpis {\n  display: grid !important;\n  grid-template-columns: repeat(3, 1fr) !important;\n  gap: 12px !important;\n}\n\n.mumak-financial .mf-kpis > .mf-kpi {\n  width: auto !important;\n  min-width: 0 !important;\n  max-width: none !important;\n  grid-column: auto !important;\n}\n\n\/* MOBILE \u2013 2 PER ROW *\/\n@media (max-width: 767px) {\n  .mumak-financial .mf-kpis {\n    grid-template-columns: repeat(2, 1fr) !important;\n  }\n}\n\n\n}\n<\/style>\n\n\n<style>\n\/* MUMAK Financial Highlights *\/\n.mumak-highlights {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --green: #21865B;\n  font-family: inherit;\n  width: 100%;\n  margin: 28px 0;\n  color: var(--navy);\n}\n\n.mumak-highlights * {\n  box-sizing: border-box;\n}\n\n.mumak-highlights .mh-header {\n  border-left: 4px solid var(--gold);\n  padding-left: 17px;\n  margin-bottom: 22px;\n}\n\n.mumak-highlights .mh-eyebrow {\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.5px;\n  color: var(--gold);\n  margin-bottom: 7px;\n}\n\n.mumak-highlights .mh-title {\n  font-size: clamp(21px, 3vw, 25px);\n  font-weight: 700;\n  color: var(--navy);\n  margin: 0;\n  line-height: 1.3;\n}\n\n.mumak-highlights .mh-grid {\n  display: grid;\n  grid-template-columns: repeat(3, minmax(0, 1fr));\n  gap: 14px;\n}\n\n.mumak-highlights .mh-card {\n  background: var(--cream);\n  border: 1px solid #E8E1D8;\n  border-radius: 12px;\n  padding: 22px 18px;\n  min-width: 0;\n}\n\n.mumak-highlights .mh-label {\n  font-size: 13px;\n  font-weight: 600;\n  margin-bottom: 16px;\n  min-height: 36px;\n}\n\n.mumak-highlights .mh-value {\n  font-size: clamp(24px, 3vw, 32px);\n  font-weight: 750;\n  letter-spacing: -0.7px;\n  line-height: 1.15;\n  white-space: nowrap;\n}\n\n.mumak-highlights .mh-unit {\n  font-size: 12px;\n  margin-top: 5px;\n  color: var(--navy);\n}\n\n.mumak-highlights .mh-growth {\n  color: var(--green);\n  font-size: 16px;\n  font-weight: 700;\n  margin-top: 17px;\n}\n\n.mumak-highlights .mh-note {\n  color: #8A9298;\n  font-size: 11px;\n  margin-top: 4px;\n}\n\n.mumak-highlights .mh-source {\n  font-size: 11px;\n  color: #8A9298;\n  margin-top: 13px;\n}\n\n@media (max-width: 767px) {\n  .mumak-highlights .mh-grid {\n    grid-template-columns: repeat(3, minmax(0, 1fr));\n    gap: 7px;\n  }\n\n  .mumak-highlights .mh-card {\n    padding: 13px 8px;\n    border-radius: 9px;\n  }\n\n  .mumak-highlights .mh-label {\n    font-size: 10px;\n    min-height: 38px;\n    margin-bottom: 10px;\n  }\n\n  .mumak-highlights .mh-value {\n    font-size: clamp(17px, 4.2vw, 23px);\n    letter-spacing: -0.4px;\n  }\n\n  .mumak-highlights .mh-unit {\n    font-size: 10px;\n  }\n\n  .mumak-highlights .mh-growth {\n    font-size: 13px;\n    margin-top: 12px;\n  }\n\n  .mumak-highlights .mh-note {\n    font-size: 9px;\n  }\n}\n\n@media (max-width: 360px) {\n  .mumak-highlights .mh-value {\n    font-size: 16px;\n  }\n}\n<\/style>\n\n\n<style>\n\/* MUMAK Minimal Financial Highlights *\/\n.mumak-kpi-strip {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --green: #21865B;\n  font-family: inherit;\n  width: 100%;\n  margin: 20px 0 24px;\n  color: var(--navy);\n  box-sizing: border-box;\n}\n\n.mumak-kpi-strip * {\n  box-sizing: border-box;\n}\n\n.mumak-kpi-strip .kpi-wrapper {\n  background: #FFFFFF;\n  border: 1px solid #E5E7E8;\n  border-radius: 12px;\n  padding: 20px 22px;\n}\n\n.mumak-kpi-strip .kpi-top {\n  display: flex;\n  justify-content: space-between;\n  align-items: center;\n  gap: 10px;\n  margin-bottom: 18px;\n}\n\n.mumak-kpi-strip .kpi-eyebrow {\n  color: var(--gold);\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: 1px;\n}\n\n.mumak-kpi-strip .kpi-heading {\n  color: #8A9298;\n  font-size: 10px;\n  letter-spacing: 1px;\n  font-weight: 600;\n}\n\n.mumak-kpi-strip .kpi-grid {\n  display: grid;\n  grid-template-columns: repeat(3, minmax(0, 1fr));\n}\n\n.mumak-kpi-strip .kpi-item {\n  padding: 3px 20px;\n  min-width: 0;\n}\n\n.mumak-kpi-strip .kpi-item:first-child {\n  padding-left: 0;\n}\n\n.mumak-kpi-strip .kpi-item:last-child {\n  padding-right: 0;\n}\n\n.mumak-kpi-strip .kpi-item + .kpi-item {\n  border-left: 1px solid #E5E7E8;\n}\n\n.mumak-kpi-strip .kpi-label {\n  color: #7B858C;\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: .4px;\n  min-height: 28px;\n  text-transform: uppercase;\n}\n\n.mumak-kpi-strip .kpi-number {\n  color: var(--navy);\n  font-size: clamp(24px, 3vw, 32px);\n  font-weight: 750;\n  letter-spacing: -1px;\n  line-height: 1.2;\n  margin-top: 5px;\n}\n\n.mumak-kpi-strip .kpi-unit {\n  color: var(--navy);\n  font-size: 12px;\n  margin-top: 2px;\n}\n\n.mumak-kpi-strip .kpi-change {\n  color: var(--green);\n  font-size: 14px;\n  font-weight: 700;\n  margin-top: 13px;\n}\n\n.mumak-kpi-strip .kpi-note {\n  color: #8A9298;\n  font-size: 10px;\n  margin-top: 3px;\n}\n\n.mumak-kpi-strip .kpi-source {\n  color: #8A9298;\n  font-size: 10px;\n  margin-top: 12px;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n  .mumak-kpi-strip .kpi-wrapper {\n    padding: 14px 12px;\n  }\n\n  .mumak-kpi-strip .kpi-top {\n    margin-bottom: 14px;\n  }\n\n  .mumak-kpi-strip .kpi-item {\n    padding: 3px 8px;\n  }\n\n  .mumak-kpi-strip .kpi-label {\n    font-size: 9px;\n    min-height: 36px;\n  }\n\n  .mumak-kpi-strip .kpi-number {\n    font-size: clamp(19px, 5vw, 25px);\n    letter-spacing: -0.5px;\n  }\n\n  .mumak-kpi-strip .kpi-unit {\n    font-size: 10px;\n  }\n\n  .mumak-kpi-strip .kpi-change {\n    font-size: 12px;\n    margin-top: 10px;\n  }\n\n  .mumak-kpi-strip .kpi-note {\n    font-size: 9px;\n  }\n}\n<\/style>\n\n<div class=\"mumak-kpi-strip\">\n  <div class=\"kpi-wrapper\">\n\n    <div class=\"kpi-top\">\n      <span class=\"kpi-eyebrow\">\n         FINANCIAL HIGHLIGHTS\n      <\/span>\n      \n    <\/div>\n\n    <div class=\"kpi-grid\">\n\n      <div class=\"kpi-item\">\n        <div class=\"kpi-label\">Revenue<\/div>\n        <div class=\"kpi-number\">3.15<\/div>\n        <div class=\"kpi-unit\">bn EUR<\/div>\n        <div class=\"kpi-change\">+36%<\/div>\n        <div class=\"kpi-note\">vs. Q3 2025<\/div>\n      <\/div>\n\n      <div class=\"kpi-item\">\n         <div class=\"kpi-label\">\n          Operating result\n        <\/div>\n        <div class=\"kpi-number\">553<\/div>\n        <div class=\"kpi-unit\">m EUR<\/div>\n        <div class=\"kpi-change\">+62%<\/div>\n        <div class=\"kpi-note\">vs. Q3 2025<\/div>\n      <\/div>\n\n      <div class=\"kpi-item\">\n         <div class=\"kpi-label\">\n          Operating margin\n        <\/div>\n        <div class=\"kpi-number\">17.5%<\/div>\n        <div class=\"kpi-unit\"> <\/div>\n        <div class=\"kpi-change\">+2.7 PP<\/div>\n        <div class=\"kpi-note\">vs. Q3 2025<\/div>\n      <\/div>\n\n    <\/div>\n  <\/div>\n\n\n  \n  \n<\/p>\n\n\n  \n<style>\n\/* MUMAK Financial Table \u2013 Rheinmetall *\/\n.mumak-fin-table {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --green: #21865B;\n  --grey: #8A9298;\n  --line: #E5E7E8;\n  font-family: inherit;\n  width: 100%;\n  margin: 24px 0;\n  color: var(--navy);\n}\n\n.mumak-fin-table * {\n  box-sizing: border-box;\n}\n\n.mumak-fin-table .mft-heading {\n  margin-bottom: 18px;\n}\n\n.mumak-fin-table .mft-eyebrow {\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: 1.3px;\n  color: var(--gold);\n  margin-bottom: 7px;\n}\n\n.mumak-fin-table .mft-title {\n  font-size: clamp(20px, 3vw, 25px);\n  font-weight: 700;\n  line-height: 1.3;\n  color: var(--navy);\n  margin: 0 0 5px;\n}\n\n.mumak-fin-table .mft-subtitle {\n  font-size: 12px;\n  color: var(--grey);\n  margin: 0;\n}\n\n.mumak-fin-table .mft-wrap {\n  border: 1px solid var(--line);\n  border-radius: 11px;\n  overflow: hidden;\n}\n\n.mumak-fin-table table {\n  width: 100%;\n  border-collapse: collapse;\n  border-spacing: 0;\n  table-layout: fixed;\n  margin: 0;\n}\n\n.mumak-fin-table thead th {\n  background: var(--navy) !important;\n  color: #FFFFFF !important;\n  padding: 15px 14px;\n  font-size: 12px;\n  font-weight: 600;\n  border: none !important;\n  text-align: left;\n}\n\n.mumak-fin-table thead th:nth-child(2),\n.mumak-fin-table thead th:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table tbody td {\n  padding: 16px 14px;\n  border: none !important;\n  border-bottom: 1px solid var(--line) !important;\n  font-size: 13px;\n  vertical-align: middle;\n  background: transparent !important;\n}\n\n.mumak-fin-table tbody tr:nth-child(odd) {\n  background: var(--cream);\n}\n\n.mumak-fin-table tbody tr:nth-child(even) {\n  background: #FFFFFF;\n}\n\n.mumak-fin-table tbody tr:last-child td {\n  border-bottom: none !important;\n}\n\n.mumak-fin-table tbody td:first-child {\n  color: var(--navy);\n  font-weight: 600;\n}\n\n.mumak-fin-table tbody td:nth-child(2) {\n  color: var(--navy);\n  font-weight: 700;\n  text-align: right;\n  white-space: nowrap;\n}\n\n.mumak-fin-table tbody td:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table .mft-positive {\n  color: var(--green);\n  font-weight: 700;\n  white-space: nowrap;\n}\n\n.mumak-fin-table .mft-comparison {\n  display: block;\n  color: var(--grey);\n  font-size: 10px;\n  font-weight: 400;\n  margin-top: 4px;\n  line-height: 1.4;\n}\n\n.mumak-fin-table .mft-source {\n  font-size: 10px;\n  color: var(--grey);\n  margin-top: 11px;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n  .mumak-fin-table thead th {\n    padding: 11px 7px;\n    font-size: 10px;\n  }\n\n  .mumak-fin-table tbody td {\n    padding: 13px 7px;\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-positive {\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-comparison {\n    font-size: 9px;\n  }\n}\n\n@media (max-width: 360px) {\n  .mumak-fin-table tbody td {\n    font-size: 10px;\n    padding: 11px 5px;\n  }\n}\n<\/style>\n\n<div class=\"mumak-fin-table\">\n\n\n\n \n<style>\n\/* MUMAK Financial Table \u2013 Revolution Medicines *\/\n.mumak-fin-table {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --green: #21865B;\n  --grey: #8A9298;\n  --line: #E5E7E8;\n  font-family: inherit;\n  width: 100%;\n  margin: 24px 0;\n  color: var(--navy);\n}\n\n.mumak-fin-table * {\n  box-sizing: border-box;\n}\n\n.mumak-fin-table .mft-heading {\n  margin-bottom: 18px;\n}\n\n.mumak-fin-table .mft-eyebrow {\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: 1.3px;\n  color: var(--gold);\n  margin-bottom: 7px;\n}\n\n.mumak-fin-table .mft-title {\n  font-size: clamp(20px, 3vw, 25px);\n  font-weight: 700;\n  line-height: 1.3;\n  color: var(--navy);\n  margin: 0 0 5px;\n}\n\n.mumak-fin-table .mft-subtitle {\n  font-size: 12px;\n  color: var(--grey);\n  margin: 0;\n}\n\n.mumak-fin-table .mft-wrap {\n  border: 1px solid var(--line);\n  border-radius: 11px;\n  overflow: hidden;\n}\n\n.mumak-fin-table table {\n  width: 100%;\n  border-collapse: collapse;\n  border-spacing: 0;\n  table-layout: fixed;\n  margin: 0;\n}\n\n.mumak-fin-table thead th {\n  background: var(--navy) !important;\n  color: #FFFFFF !important;\n  padding: 15px 14px;\n  font-size: 12px;\n  font-weight: 600;\n  border: none !important;\n  text-align: left;\n}\n\n.mumak-fin-table thead th:nth-child(2),\n.mumak-fin-table thead th:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table tbody td {\n  padding: 16px 14px;\n  border: none !important;\n  border-bottom: 1px solid var(--line) !important;\n  font-size: 13px;\n  vertical-align: middle;\n  background: transparent !important;\n}\n\n.mumak-fin-table tbody tr:nth-child(odd) {\n  background: var(--cream);\n}\n\n.mumak-fin-table tbody tr:nth-child(even) {\n  background: #FFFFFF;\n}\n\n.mumak-fin-table tbody tr:last-child td {\n  border-bottom: none !important;\n}\n\n.mumak-fin-table tbody td:first-child {\n  color: var(--navy);\n  font-weight: 600;\n}\n\n.mumak-fin-table tbody td:nth-child(2) {\n  color: var(--navy);\n  font-weight: 700;\n  text-align: right;\n  white-space: nowrap;\n}\n\n.mumak-fin-table tbody td:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table .mft-positive {\n  color: var(--green);\n  font-weight: 700;\n  white-space: nowrap;\n}\n\n.mumak-fin-table .mft-comparison {\n  display: block;\n  color: var(--grey);\n  font-size: 10px;\n  font-weight: 400;\n  margin-top: 4px;\n  line-height: 1.4;\n}\n\n.mumak-fin-table .mft-source {\n  font-size: 10px;\n  color: var(--grey);\n  margin-top: 11px;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n  .mumak-fin-table thead th {\n    padding: 11px 7px;\n    font-size: 10px;\n  }\n\n  .mumak-fin-table tbody td {\n    padding: 13px 7px;\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-positive {\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-comparison {\n    font-size: 9px;\n  }\n}\n\n@media (max-width: 360px) {\n  .mumak-fin-table tbody td {\n    font-size: 10px;\n    padding: 11px 5px;\n  }\n}\n<\/style>\n\n\n<style>\n\/* MUMAK Financial Table \u2013 Rheinmetall *\/\n.mumak-fin-table {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --green: #21865B;\n  --grey: #8A9298;\n  --line: #E5E7E8;\n  font-family: inherit;\n  width: 100%;\n  margin: 24px 0;\n  color: var(--navy);\n}\n\n.mumak-fin-table * {\n  box-sizing: border-box;\n}\n\n.mumak-fin-table .mft-heading {\n  margin-bottom: 18px;\n}\n\n.mumak-fin-table .mft-eyebrow {\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: 1.3px;\n  color: var(--gold);\n  margin-bottom: 7px;\n}\n\n.mumak-fin-table .mft-title {\n  font-size: clamp(20px, 3vw, 25px);\n  font-weight: 700;\n  line-height: 1.3;\n  color: var(--navy);\n  margin: 0 0 5px;\n}\n\n.mumak-fin-table .mft-subtitle {\n  font-size: 12px;\n  color: var(--grey);\n  margin: 0;\n}\n\n.mumak-fin-table .mft-wrap {\n  border: 1px solid var(--line);\n  border-radius: 11px;\n  overflow: hidden;\n}\n\n.mumak-fin-table table {\n  width: 100%;\n  border-collapse: collapse;\n  border-spacing: 0;\n  table-layout: fixed;\n  margin: 0;\n}\n\n.mumak-fin-table thead th {\n  background: var(--navy) !important;\n  color: #FFFFFF !important;\n  padding: 15px 14px;\n  font-size: 12px;\n  font-weight: 600;\n  border: none !important;\n  text-align: left;\n}\n\n.mumak-fin-table thead th:nth-child(2),\n.mumak-fin-table thead th:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table tbody td {\n  padding: 16px 14px;\n  border: none !important;\n  border-bottom: 1px solid var(--line) !important;\n  font-size: 13px;\n  vertical-align: middle;\n  background: transparent !important;\n}\n\n.mumak-fin-table tbody tr:nth-child(odd) {\n  background: var(--cream);\n}\n\n.mumak-fin-table tbody tr:nth-child(even) {\n  background: #FFFFFF;\n}\n\n.mumak-fin-table tbody tr:last-child td {\n  border-bottom: none !important;\n}\n\n.mumak-fin-table tbody td:first-child {\n  color: var(--navy);\n  font-weight: 600;\n}\n\n.mumak-fin-table tbody td:nth-child(2) {\n  color: var(--navy);\n  font-weight: 700;\n  text-align: right;\n  white-space: nowrap;\n}\n\n.mumak-fin-table tbody td:nth-child(3) {\n  text-align: right;\n}\n\n.mumak-fin-table .mft-positive {\n  color: var(--green);\n  font-weight: 700;\n  white-space: nowrap;\n}\n\n.mumak-fin-table .mft-comparison {\n  display: block;\n  color: var(--grey);\n  font-size: 10px;\n  font-weight: 400;\n  margin-top: 4px;\n  line-height: 1.4;\n}\n\n.mumak-fin-table .mft-source {\n  font-size: 10px;\n  color: var(--grey);\n  margin-top: 11px;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n  .mumak-fin-table thead th {\n    padding: 11px 7px;\n    font-size: 10px;\n  }\n\n  .mumak-fin-table tbody td {\n    padding: 13px 7px;\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-positive {\n    font-size: 11px;\n  }\n\n  .mumak-fin-table .mft-comparison {\n    font-size: 9px;\n  }\n}\n\n@media (max-width: 360px) {\n  .mumak-fin-table tbody td {\n    font-size: 10px;\n    padding: 11px 5px;\n  }\n}\n\n\/* MUMAK \u2013 Clean White Financial Table *\/\n\n\/* White background instead of beige *\/\n.mumak-rvmd,\n.mumak-rvmd .mf-table-wrap,\n.mumak-rvmd table,\n.mumak-rvmd tbody,\n.mumak-rvmd tbody tr,\n.mumak-rvmd tbody td,\n.mumak-rvmd tbody tr:nth-child(even),\n.mumak-rvmd tbody tr:nth-child(even) td {\n  background: #FFFFFF !important;\n  background-color: #FFFFFF !important;\n}\n\n\/* Header \u2013 light grey, similar to MUMAK menu *\/\n.mumak-rvmd thead,\n.mumak-rvmd thead tr,\n.mumak-rvmd thead th {\n  background: #F3F5F6 !important;\n  background-color: #F3F5F6 !important;\n  color: #29485A !important;\n}\n\n\/* Subtle row separators *\/\n.mumak-rvmd tbody td {\n  border-bottom: 1px solid #E5E7E8 !important;\n}\n\n\/* Very subtle hover *\/\n.mumak-rvmd tbody tr:hover td {\n  background: #F7F9FA !important;\n}\n\n<\/style>\n\n<div class=\"mumak-fin-table\">\n\n\n<style>\n\/* MUMAK Financial Results \u2013 Revolution Medicines *\/\n.mumak-rvmd {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --line: #E5E7E8;\n  font-family: inherit;\n  color: var(--navy);\n  margin: 28px 0;\n  width: 100%;\n}\n\n.mumak-rvmd * {\n  box-sizing: border-box;\n}\n\n.mumak-rvmd .mf-header {\n  border-left: 4px solid var(--gold);\n  padding-left: 17px;\n  margin-bottom: 22px;\n}\n\n.mumak-rvmd .mf-eyebrow {\n  color: var(--gold);\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.5px;\n  text-transform: uppercase;\n  margin-bottom: 7px;\n}\n\n.mumak-rvmd .mf-title {\n  font-size: clamp(21px, 3vw, 27px);\n  font-weight: 700;\n  line-height: 1.3;\n  margin: 0 0 7px;\n  color: var(--navy);\n}\n\n.mumak-rvmd .mf-subtitle {\n  font-size: 13px;\n  color: #71808A;\n  margin: 0;\n  font-style: italic;\n}\n\n\n\/* Neutral table background \u2013 MUMAK *\/\n.mumak-rvmd .mf-table-wrap {\n  background: #FFFFFF;\n}\n\n.mumak-rvmd thead th {\n  background: #FAF7F2;\n  color: #29485A;\n  border-bottom: 1px solid #E5E7E8;\n}\n\n.mumak-rvmd tbody tr,\n.mumak-rvmd tbody tr:nth-child(even) {\n  background: #FFFFFF;\n}\n\n.mumak-rvmd tbody tr:hover {\n  background: #FAF7F2;\n}\n\n\n.mumak-rvmd table {\n  width: 100%;\n  border-collapse: collapse;\n  border: none;\n  margin: 0;\n  font-size: 14px;\n}\n\n.mumak-rvmd thead th {\n  background: var(--navy);\n  color: #FFFFFF;\n  font-size: 12px;\n  font-weight: 600;\n  padding: 16px 14px;\n  text-align: right;\n  border: none;\n}\n\n.mumak-rvmd thead th:first-child {\n  text-align: left;\n}\n\n.mumak-rvmd tbody td {\n  padding: 15px 14px;\n  border: none;\n  border-bottom: 1px solid var(--line);\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n.mumak-rvmd tbody td:first-child {\n  text-align: left;\n  font-weight: 600;\n}\n\n.mumak-rvmd tbody tr:nth-child(even) {\n  background: var(--cream);\n}\n\n.mumak-rvmd tbody tr:last-child td {\n  border-bottom: none;\n}\n\n.mumak-rvmd .mf-highlight {\n  color: var(--navy);\n  font-weight: 700;\n}\n\n.mumak-rvmd .mf-negative {\n  color: #A45C52;\n  font-weight: 600;\n}\n\n.mumak-rvmd .mf-neutral {\n  color: #71808A;\n  font-size: 12px;\n}\n\n.mumak-rvmd .mf-source {\n  font-size: 11px;\n  color: #7B858B;\n  margin-top: 12px;\n  line-height: 1.6;\n}\n\n@media (max-width: 767px) {\n  .mumak-rvmd table {\n    font-size: 11px;\n  }\n\n  .mumak-rvmd thead th,\n  .mumak-rvmd tbody td {\n    padding: 12px 7px;\n  }\n\n  .mumak-rvmd thead th {\n    font-size: 10px;\n  }\n\n  .mumak-rvmd .mf-neutral {\n    font-size: 10px;\n  }\n}\n\n  .mumak-rvmd .mf-neutral {\n    font-size: 10px;\n  }\n}\n\n\n<\/style>\n\n<section class=\"mumak-rvmd\">\n\n  <div class=\"mf-header\">\n     <div class=\"mf-eyebrow\">\n      Revolution Medicines \u00b7 Q3 2026\n    <\/div>\n\n    <h3 class=\"mf-title\">\n      Financial Key Figures in Detail\n    <\/h3>\n\n    <p class=\"mf-subtitle\">\n      Quarterly Comparison vs. Q3 2025\n    <\/p> \n  <\/div>\n\n  <div class=\"mf-table-wrap\">\n    <table>\n      <thead>\n        <tr>\n          <th>Key Figure<\/th>\n          <th>Q3 2026<\/th>\n          <th>Q3 2025<\/th>\n          <th>Change<\/th>\n        <\/tr>\n      <\/thead>\n\n      <tbody>\n        <tr>\n          <td>Net Product Revenue<\/td>\n          <td class=\"mf-highlight\">USD 197.6 million<\/td>\n          <td>USD 0 million<\/td>\n          <td class=\"mf-neutral\">First Revenue<\/td>\n        <\/tr>\n\n        <tr>\n          <td>Research & Development<\/td>\n          <td>USD 417.1 million<\/td>\n          <td>USD 262.5 million<\/td>\n  <td style=\"color: #2E8B57 !important; font-weight: 600;\">+58.9%<\/td>\n<\/tr>\n\n        <tr>\n          <td>Sales & Administration<\/td>\n          <td>USD 153.3 million<\/td>\n          <td>USD 52.8 million<\/td>\n  <td style=\"color: #2E8B57 !important; font-weight: 600;\">+190.3%<\/td>\n<\/tr>\n\n        <tr>\n          <td>Operating Result<\/td>\n          <td class=\"mf-negative\">\u2212USD 373.1 million<\/td>\n          <td>\u2212USD 315.3 million<\/td>\n          <td class=\"mf-negative\">Loss Increased<\/td>\n        <\/tr>\n\n        <tr>\n          <td>Net Result<\/td>\n          <td class=\"mf-negative\">\u2212USD 407.5 million<\/td>\n          <td>\u2212USD 305.2 million<\/td>\n          <td class=\"mf-negative\">Loss Increased<\/td>\n        <\/tr>\n\n        <tr>\n          <td>Loss Per Share<\/td>\n          <td class=\"mf-negative\">\u2212USD 1.90<\/td>\n          <td>\u2212USD 1.61<\/td>\n          <td class=\"mf-negative\">\u2212USD 0.29<\/td>\n        <\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <p class=\"mf-source\">\n     Source: Revolution Medicines, Q3 2026 Quarterly Report.\n\n  <\/p>\n\n<\/section>\n\n<\/div>\n\n<\/div>\n\n\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5888df6 elementor-widget elementor-widget-text-editor\" data-id=\"5888df6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">As of <strong>September 30, 2026<\/strong>, the company had cash and marketable securities of approximately USD 3.65 billion. Additionally, <a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> received <strong>USD 250 million in October<\/strong> from a financing agreement with <strong>Royalty Pharma<\/strong>.<\/p><p>The high liquidity reserve supports the financing of ongoing clinical trials and the international expansion of the sales business. At the same time, capital requirements remain substantial due to extensive research programs.<\/p><h2>Business Development<\/h2><h4>RASONQUE \u2013 Commencement of Commercialization<\/h4><p>On <strong>August 26, 2026<\/strong>, <strong>RASONQUE (Daraxonrasib)<\/strong> received approval from the US Food and Drug Administration <strong>(FDA)<\/strong> for certain adult patients with metastatic pancreatic cancer.<\/p><p>The drug inhibits activated <strong>RAS signaling proteins<\/strong>, which play a central role in numerous cancers.<\/p><p>Within the first approximately five weeks after market launch, <strong>more than 5,000 patients in the US were commercially treated with RASONQUE<\/strong>.<\/p><p>However, the <strong>revenue of USD 197.6 million<\/strong> also includes patients previously treated through special access programs, as well as initial inventory in the distribution channel. The company therefore explicitly points out that the initial revenue development cannot be directly extrapolated to future quarters.<\/p><h4>European Approval Nears<\/h4><p>In <strong>October 2026<\/strong>, the <strong>Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive recommendation<\/strong> for the approval of <strong>Daraxonrasib<\/strong> in the <strong>European Union<\/strong>.<\/p><p>The recommendation is based on the results of the <strong>Phase 3 RASolute 302 study<\/strong>, in which Daraxonrasib showed a survival benefit <strong>compared to chemotherapy<\/strong> in previously treated patients with metastatic pancreatic cancer.<\/p><h6>The final decision by the European Commission is still pending.<\/h6><h4>Clinical Development<\/h4><p>In addition to the successful market launch of RASONQUE, <a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> is advancing its research programs in several cancer indications.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5978826 elementor-widget elementor-widget-html\" data-id=\"5978826\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t\n<style>\/* MUMAK \u2013 Revolution Medicines Clinical Pipeline *\/\n.mumak-rvmd-pipeline {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --green: #21865B;\n  --grey: #8A9298;\n  --line: #E5E7E8;\n\n  font-family: inherit;\n  width: 100%;\n  margin: 24px 0;\n  color: var(--navy);\n  background: transparent !important;\n}\n\n.mumak-rvmd-pipeline * {\n  box-sizing: border-box;\n}\n\n\/* Header *\/\n.mumak-rvmd-pipeline .mp-header {\n  margin-bottom: 18px;\n  background: transparent;\n}\n\n.mumak-rvmd-pipeline .mp-eyebrow {\n  color: var(--gold);\n  font-size: 10px;\n  font-weight: 700;\n  letter-spacing: 1.3px;\n  text-transform: uppercase;\n  margin-bottom: 7px;\n}\n\n.mumak-rvmd-pipeline .mp-title {\n  color: var(--navy);\n  font-size: clamp(20px, 3vw, 25px);\n  font-weight: 700;\n  line-height: 1.3;\n  margin: 0 0 5px;\n}\n\n.mumak-rvmd-pipeline .mp-subtitle {\n  color: var(--grey);\n  font-size: 12px;\n  margin: 0;\n}\n\n\/* Table Container *\/\n.mumak-rvmd-pipeline .mp-table-wrap {\n  width: 100%;\n  border: 1px solid var(--line);\n  border-radius: 11px;\n  overflow-x: auto;\n  background: #FFFFFF !important;\n}\n\n\/* Table *\/\n.mumak-rvmd-pipeline table {\n  width: 100%;\n  border-collapse: collapse;\n  border-spacing: 0;\n  margin: 0;\n  background: #FFFFFF !important;\n  table-layout: fixed;\n}\n\n\/* Table Header *\/\n.mumak-rvmd-pipeline thead,\n.mumak-rvmd-pipeline thead tr,\n.mumak-rvmd-pipeline thead th {\n  background: var(--navy) !important;\n  color: #FFFFFF !important;\n}\n\n.mumak-rvmd-pipeline th {\n  padding: 15px 13px;\n  font-size: 12px;\n  font-weight: 600;\n  border: none !important;\n  text-align: left;\n  vertical-align: middle;\n}\n\n\/* Table Body \u2013 Clean White *\/\n.mumak-rvmd-pipeline tbody,\n.mumak-rvmd-pipeline tbody tr,\n.mumak-rvmd-pipeline tbody td,\n.mumak-rvmd-pipeline tbody tr:nth-child(odd),\n.mumak-rvmd-pipeline tbody tr:nth-child(even) {\n  background: #FFFFFF !important;\n  background-color: #FFFFFF !important;\n}\n\n.mumak-rvmd-pipeline td {\n  padding: 15px 13px;\n  border: none !important;\n  border-bottom: 1px solid var(--line) !important;\n  vertical-align: middle;\n  font-size: 12px;\n  line-height: 1.5;\n  color: var(--navy);\n  overflow-wrap: anywhere;\n}\n\n\/* First Column *\/\n.mumak-rvmd-pipeline td:first-child {\n  font-weight: 700;\n  color: var(--navy);\n}\n\n\/* Last Row *\/\n.mumak-rvmd-pipeline tbody tr:last-child td {\n  border-bottom: none !important;\n}\n\n\/* Subtle Hover *\/\n.mumak-rvmd-pipeline tbody tr:hover td {\n  background: #F7F9FA !important;\n}\n\n\/* Status *\/\n.mumak-rvmd-pipeline .mp-approved {\n  color: var(--green);\n  font-weight: 700;\n}\n\n.mumak-rvmd-pipeline .mp-phase {\n  color: var(--navy);\n  font-weight: 600;\n}\n\n.mumak-rvmd-pipeline .mp-phase1 {\n  color: var(--gold);\n  font-weight: 600;\n}\n\n.mumak-rvmd-pipeline .mp-note {\n  display: block;\n  color: var(--grey);\n  font-size: 10px;\n  font-weight: 400;\n  margin-top: 4px;\n  line-height: 1.4;\n}\n\n\/* Source *\/\n.mumak-rvmd-pipeline .mp-source {\n  font-size: 10px;\n  color: var(--grey);\n  margin-top: 12px;\n  line-height: 1.6;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n\n  .mumak-rvmd-pipeline th,\n  .mumak-rvmd-pipeline td {\n    padding: 12px 8px;\n    font-size: 10px;\n  }\n\n  .mumak-rvmd-pipeline th {\n    font-size: 10px;\n  }\n\n  .mumak-rvmd-pipeline .mp-note {\n    font-size: 9px;\n  }\n\n  .mumak-rvmd-pipeline table {\n    min-width: 520px;\n  }\n}\n<\/style><section class=\"mumak-rvmd-pipeline\"><h3 class=\"mp-title\">Klinische Pipeline im \u00dcberblick\n    <\/h3><p class=\"mp-subtitle\">Entwicklungsprogramme und klinische Studien\n    <\/p><\/div><div class=\"mp-table-wrap\"><table><colgroup><col style=\"width: 35%;\"><col style=\"width: 39%;\"><col style=\"width: 26%;\"><\/colgroup><thead><tr><th>Wirkstoff \/ Programm<\/th><th>Indikation<\/th><th>Entwicklungsstand<\/th><\/tr><\/thead><tbody><tr><td>RASONQUE (Daraxonrasib)<\/td><td>Metastasierter\n            Bauchspeicheldr\u00fcsenkrebs\n          <\/td><td><span class=\"mp-approved\">FDA-zugelassen\n            <\/span><span class=\"mp-note\">US-Vertrieb gestartet\n            <\/span><\/td><\/tr><tr><td>RASolute 303<\/td><td>Erstlinienbehandlung\n            Bauchspeicheldr\u00fcsenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><\/td><\/tr><tr><td>RASolute 304<\/td><td>Adjuvante Behandlung\n            Bauchspeicheldr\u00fcsenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><\/td><\/tr><tr><td>RASolve 301<\/td><td>RAS-mutierter Lungenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><\/td><\/tr><tr><td>Zoldonrasib \/ RASolute 305<\/td><td>RAS-G12D-\n            Bauchspeicheldr\u00fcsenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><\/td><\/tr><tr><td>Daraxonrasib + Zoldonrasib \/\n            RASolute 309\n          <\/td><td>RAS-G12D-\n            Bauchspeicheldr\u00fcsenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><\/td><\/tr><tr><td>Elironrasib \/ RASolve 307<\/td><td>RAS-G12C-Lungenkrebs\n          <\/td><td><span class=\"mp-phase\">Phase 3<\/span><span class=\"mp-note\">Studie initiiert\n            <\/span><\/td><\/tr><tr><td>RMC-5127<\/td><td>RAS-G12V-mutierte Tumoren\n          <\/td><td><span class=\"mp-phase1\">Phase 1<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"mp-source\">Quelle: Revolution Medicines,\n    Unternehmensupdate vom 4. November 2026.\n  <\/div><\/section>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6a601f7 elementor-widget elementor-widget-text-editor\" data-id=\"6a601f7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">The clinical strategy focuses particularly on pancreatic cancer, non-small cell lung cancer, and colorectal cancer.<\/p><p>The development of further RAS(ON) inhibitors aims to open up additional patient groups and long-term reduce dependence on a single drug.<\/p><p>However, clinical efficacy, tolerability, regulatory decisions, and the commercial success of further active ingredients remain subject to considerable uncertainties.<\/p><h3>Outlook for 2026<\/h3><p><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> confirmed its forecast for GAAP operating expenses for the full year 2026.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e3962c elementor-widget elementor-widget-html\" data-id=\"4e3962c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t\n<style>\/* MUMAK \u2013 Revolution Medicines Outlook 2026 *\/\n.mumak-rvmd-outlook {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --green: #21865B;\n  --grey: #8A9298;\n  --line: #E5E7E8;\n\n  font-family: inherit;\n  color: var(--navy);\n  width: 100%;\n  margin: 28px 0;\n  background: transparent !important;\n}\n\n.mumak-rvmd-outlook * {\n  box-sizing: border-box;\n}\n\n\/* Heading *\/\n.mumak-rvmd-outlook .mf-heading {\n  border-left: 4px solid var(--gold);\n  padding-left: 17px;\n  margin-bottom: 22px;\n  background: transparent !important;\n}\n\n.mumak-rvmd-outlook .mf-eyebrow {\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.5px;\n  color: var(--gold);\n  margin-bottom: 7px;\n}\n\n.mumak-rvmd-outlook .mf-title {\n  font-size: clamp(20px, 3vw, 25px);\n  font-weight: 700;\n  line-height: 1.3;\n  margin: 0 0 6px;\n  color: var(--navy);\n}\n\n.mumak-rvmd-outlook .mf-subtitle {\n  font-size: 13px;\n  color: var(--grey);\n  margin: 0;\n}\n\n\/* Table *\/\n.mumak-rvmd-outlook .mf-table-wrap {\n  width: 100%;\n  overflow-x: auto;\n  border: 1px solid var(--line);\n  border-radius: 12px;\n  background: #FFFFFF !important;\n}\n\n.mumak-rvmd-outlook table {\n  width: 100%;\n  border-collapse: collapse;\n  border-spacing: 0;\n  margin: 0;\n  table-layout: fixed;\n  background: #FFFFFF !important;\n}\n\n\/* Navy Header *\/\n.mumak-rvmd-outlook thead,\n.mumak-rvmd-outlook thead tr,\n.mumak-rvmd-outlook thead th {\n  background: var(--navy) !important;\n  color: #FFFFFF !important;\n}\n\n.mumak-rvmd-outlook th {\n  padding: 15px 14px;\n  font-size: 12px;\n  font-weight: 600;\n  text-align: left;\n  border: none !important;\n}\n\n\/* White Body *\/\n.mumak-rvmd-outlook tbody,\n.mumak-rvmd-outlook tbody tr,\n.mumak-rvmd-outlook tbody td,\n.mumak-rvmd-outlook tbody tr:nth-child(odd),\n.mumak-rvmd-outlook tbody tr:nth-child(even) {\n  background: #FFFFFF !important;\n  background-color: #FFFFFF !important;\n}\n\n.mumak-rvmd-outlook td {\n  padding: 16px 14px;\n  border: none !important;\n  border-bottom: 1px solid var(--line) !important;\n  font-size: 13px;\n  line-height: 1.5;\n  vertical-align: middle;\n  color: var(--navy);\n  overflow-wrap: break-word;\n}\n\n.mumak-rvmd-outlook td:first-child {\n  font-weight: 600;\n}\n\n.mumak-rvmd-outlook tbody tr:last-child td {\n  border-bottom: none !important;\n}\n\n.mumak-rvmd-outlook tbody tr:hover td {\n  background: #F7F9FA !important;\n}\n\n\/* Values and Status *\/\n.mumak-rvmd-outlook .mf-value {\n  font-weight: 700;\n  color: var(--navy);\n}\n\n.mumak-rvmd-outlook .mf-confirmed {\n  color: var(--green);\n  font-weight: 700;\n}\n\n.mumak-rvmd-outlook .mf-status {\n  font-weight: 600;\n  color: var(--navy);\n}\n\n.mumak-rvmd-outlook .mf-pending {\n  color: var(--gold);\n  font-weight: 600;\n}\n\n.mumak-rvmd-outlook .mf-small {\n  display: block;\n  font-size: 11px;\n  color: var(--grey);\n  margin-top: 4px;\n  font-weight: 400;\n}\n\n\/* Note \u2013 White Instead of Beige *\/\n.mumak-rvmd-outlook .mf-note {\n  background: #FFFFFF !important;\n  border: 1px solid var(--line);\n  border-left: 3px solid var(--gold);\n  padding: 17px 19px;\n  border-radius: 0 9px 9px 0;\n  margin-top: 18px;\n}\n\n.mumak-rvmd-outlook .mf-note strong {\n  display: block;\n  font-size: 13px;\n  margin-bottom: 6px;\n  color: var(--navy);\n}\n\n.mumak-rvmd-outlook .mf-note p {\n  margin: 0;\n  font-size: 13px;\n  line-height: 1.65;\n  color: var(--navy);\n}\n\n\/* Source *\/\n.mumak-rvmd-outlook .mf-source {\n  font-size: 11px;\n  color: var(--grey);\n  margin-top: 12px;\n  line-height: 1.6;\n}\n\n\/* Mobile *\/\n@media (max-width: 767px) {\n  .mumak-rvmd-outlook th,\n  .mumak-rvmd-outlook td {\n    padding: 12px 9px;\n    font-size: 11px;\n  }\n\n  .mumak-rvmd-outlook .mf-small {\n    font-size: 10px;\n  }\n\n  .mumak-rvmd-outlook .mf-note {\n    padding: 14px;\n  }\n}\n<\/style><section class=\"mumak-rvmd-outlook\"><div class=\"mf-heading\"><div class=\"mf-eyebrow\">REVOLUTION MEDICINES \u00b7 Q3 2026\n    <\/div><h3 class=\"mf-title\">Jahresprognose und wichtige Meilensteine\n    <\/h3><p class=\"mf-subtitle\">Finanzielle Erwartungen und klinischer Ausblick\n    <\/p><\/div><div class=\"mf-table-wrap\"><table><colgroup><col style=\"width: 49%;\"><col style=\"width: 51%;\"><\/colgroup><thead><tr><th>Kennzahl \/ Ereignis<\/th><th>Erwartung<\/th><\/tr><\/thead><tbody><tr><td>Operative Aufwendungen 2026<\/td><td><span class=\"mf-value\">2,1\u20132,2 Mrd. USD\n            <\/span><span class=\"mf-small\">Prognose best\u00e4tigt\n            <\/span><\/td><\/tr><tr><td>Aktienbasierte Verg\u00fctung<\/td><td><span class=\"mf-value\">270\u2013290 Mio. USD\n            <\/span><span class=\"mf-small\">In operativen Aufwendungen enthalten\n            <\/span><\/td><\/tr><tr><td>RASONQUE \u2013 USA<\/td><td><span class=\"mf-confirmed\">Vermarktung l\u00e4uft\n            <\/span><span class=\"mf-small\">Weiterer Ausbau des Vertriebs\n            <\/span><\/td><\/tr><tr><td>RASONQUE \u2013 Europa<\/td><td><span class=\"mf-pending\">Zulassungsentscheidung ausstehend\n            <\/span><span class=\"mf-small\">Europ\u00e4ische Kommission\n            <\/span><\/td><\/tr><tr><td>RASolute 303<\/td><td><span class=\"mf-status\">H1 2027\n            <\/span><span class=\"mf-small\">Erwarteter Abschluss der weltweiten\n              Patientenrekrutierung\n            <\/span><\/td><\/tr><tr><td>RASolve 301<\/td><td><span class=\"mf-status\">2027\n            <\/span><span class=\"mf-small\">Erste klinische Studiendaten erwartet\n            <\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"mf-note\"><strong>Strategischer Ausblick<\/strong><p>Im Mittelpunkt stehen der weitere Ausbau\n      der RASONQUE-Vermarktung in den USA,\n      die m\u00f6gliche europ\u00e4ische Zulassung sowie\n      die Fortsetzung der laufenden Phase-3-Studien.\n      Die nachhaltige Umsatzentwicklung und\n      der hohe Forschungsaufwand bleiben\n      zentrale Faktoren f\u00fcr die weitere\n      Unternehmensentwicklung.\n    <\/p><\/div><div class=\"mf-source\">Quelle:\n    Revolution Medicines, Quartalsbericht Q3 2026.\n  <\/div><\/section>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-944761a elementor-widget elementor-widget-text-editor\" data-id=\"944761a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">The focus is on the further market penetration of <strong>RASONQUE<\/strong>, potential European approval, and the continuation of several <strong>Phase 3 studies<\/strong>.<\/p><p>The development of ongoing treatment revenues will be particularly relevant, as high initial revenues were partly supported by one-time launch effects.<\/p><h2>Strategic Classification<\/h2><p><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> remains part of the <strong>UMBRELLA Strategy&#8217;s<\/strong> commitment to the biotechnology and oncology sector.<\/p><p>The <strong>FDA approval of RASONQUE<\/strong> represents a significant step forward. For the first time, the company has a commercially marketed drug and generates substantial product revenues from it.<\/p><p>The extensive <strong>RAS(ON) pipeline<\/strong> opens up additional development opportunities in several <strong>oncological indications<\/strong>.<\/p><p>At the same time, rising research and sales costs indicate that the transition to commercialization continues to require significant investment.<\/p><p>For the <strong>UMBRELLA Strategy<\/strong>, the sustainable <strong>revenue development of RASONQUE<\/strong>, European approval decisions, <strong>the results of ongoing Phase 3 studies<\/strong>, and further stock price dynamics are particularly central.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4e31745 e-con-full e-flex e-con e-child\" data-id=\"4e31745\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8d6e245 elementor-widget elementor-widget-text-editor\" data-id=\"8d6e245\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\"><span style=\"color: #003366;\"><span style=\"color: #b58a2a;\"><strong>Key Takeaway<\/strong><\/span><\/span><\/p><p data-pm-slice=\"1 1 []\"><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\"><strong>Revolution Medicines<\/strong><\/a> achieved a decisive development step in the third quarter of 2026 with the FDA approval and market launch of RASONQUE. Initial product revenues of USD 197.6 million and a liquidity reserve of approximately USD 3.65 billion strengthen the financial position. At the same time, high research expenses, ongoing losses, and clinical development risks remain key factors for the company&#8217;s future development.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>RASONQUE launch brings first revenues, research expenses remain high.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[684,664,400],"aktie":[],"class_list":["post-12571","post","type-post","status-publish","format-standard","hentry","category-company-update","tag-quartalszahlen-2026","tag-biotechnologie-2","tag-revolution-medicines"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=12571"}],"version-history":[{"count":10,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12571\/revisions"}],"predecessor-version":[{"id":12619,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12571\/revisions\/12619"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=12571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=12571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=12571"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=12571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}